CA Intermediate · Advanced Accounting · AS 26 Intangible Assets
Kaveri Pharma Ltd. acquired a patent on 1 April 2023 for Rs 40,00,000 with a legal life of 10 years. Management expects it to generate benefits for only 8 years, with nil residual value, and uses straight-line amortisation. On 1 April 2025 the company spent Rs 4,00,000 on a successful defence of the patent in a lawsuit; this restores the original expected benefits, and the remaining useful life stays at 6 years from that date. What is the carrying amount of the patent on 31 March 2026, if the defence cost is capitalised?
Recomputation needed.
- ARs 34,00,000Correct
- BRs 30,00,000
- CRs 28,00,000
- DRs 29,33,333
Explanation
Amortisation is Rs 5,00,000 a year over 8 years. Up to 31 March 2025 two years are amortised, so book value is Rs 30,00,000. Adding the Rs 4,00,000 defence cost gives Rs 34,00,000, amortised over the remaining 6 years at Rs 5,66,667 for 2025-26. Carrying amount is Rs 34,00,000 - 5,66,667 = Rs 28,33,333. The option showing Rs 34,00,000 is the pre-amortisation figure and is wrong; so recompute carefully.
Did you get it right without looking?
One question tells you little. A timed set on AS 26 Intangible Assets shows your real accuracy, how long you take and where you lose marks.
More AS 26 Intangible Assets questions
- Ganga Media Ltd acquired a broadcasting right for Rs 9,00,000, paying Rs 1,00,000 as non-refundable taxes and Rs 50,000 as legal fees, and r…
- Kaveri Pharma Ltd incurred Rs 18 lakh on a research phase for a new formulation during 2025-26 and Rs 12 lakh on development after all AS 26…
- Bharat Foods Ltd. purchased a brand licence on 1 July 2024 for Rs 24,00,000 with useful life of 6 years and nil residual value, amortised st…
- Sundaram Software Ltd. incurred Rs 18,00,000 on a project to develop a new billing application. Research phase cost Rs 6,00,000. Development…
- Narmada Infotech Ltd acquired a patent on 1 April 2022 for ₹48 lakh and amortised it on the straight-line method over an estimated useful li…
- Kaveri Pharma Ltd is developing a new formulation. Research costs of ₹14 lakh were incurred from April to June. Development costs of ₹9 lakh…